How I Treat Acute Lymphoblastic Leukemia (ALL) - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

How I Treat Acute Lymphoblastic Leukemia (ALL)

Insight from the Experts

Not a member of My prIME? Join now for instant access.

Stay current on hot topics in acute lymphoblastic leukemia (ALL) with these downloadable slides from this satellite symposium preceding the 2018 Annual Hematology Meeting. A combination of presentations on clinical trial data and current best practices with case scenarios offer expert insight into critical factors underpinning current recommendations and the cutting edge of ALL management in adolescents and adults.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Dec 5, 2018

Expiration Date

Dec 5, 2019

Featured Expert

  • Stephen E. Sallan, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

How I treat AYAs with newly diagnosed ALL

Featured Expert

  • David I. Marks, MBBS, PhD, FRACP, FRCPath, University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom

Featured Topic

How I treat newly diagnosed ALL in adults

Featured Expert

  • Dan Douer, MD, USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

Featured Topic

How I treat patients with minimal residual disease after induction therapy

Featured Expert

  • Dan Douer, MD, USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

Featured Topic

How I treat relapsed/refractory ALL

Featured Expert

  • Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

What’s around the corner: Novel treatment approaches for ALL

Featured Expert

  • Stephen E. Sallan, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Featured Topic

prIME Points

This educational activity is designed to address the needs of hematologists, oncologists, and other healthcare professionals who manage adolescent/young adults (AYAs) and adults with acute lymphoblastic leukemia (ALL).

After successful completion of this educational activity, participants should be able to:

  • Employ optimal induction strategies for the initial treatment of AYAs and adults with ALL
  • Analyze the role of minimal residual disease assessment in both the prognosis and treatment planning for AYAs and adults with ALL
  • Select optimal strategies for relapsed/refractory ALL in the AYA and adult population
  • Describe the role of new and emerging therapies used to treat ALL in AYAs and adults

This educational activity is supported by a grant from Servier.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Douer has disclosed that he received consulting fees from Erytech and Spectrum. He received honoraria for promotional speakers’ bureaus from Amgen, Pfizer, Shire, and Spectrum. He also disclosed membership on an advisory committee or review panel for Amgen and Jazz. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Marks has disclosed that he has received consulting fees from Pfizer. He disclosed honoraria for a promotional speakers’ bureau and has been a speaker for Pfizer. He also disclosed membership on an advisory committee or review panel for Amgen, Novartis, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Luskin has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Sallan has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.